-+ 0.00%
-+ 0.00%
-+ 0.00%

UNITY BIOTECHNOLOGY: TO EXPLORE STRATEGIC ALTERNATIVES TO ADVANCE UBX1325, TIE2/ANTI-VEGF BISPECIFIC, & TIE2 AGONISTIC ANTIBODY ASSETS

Reuters·05/05/2025 12:00:02

Please log in to view news